Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 28, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,431.85 pence per share.
Material Changes
On February 28, 2007, the Company purchased 630,000 of its Ordinary shares of 25 pence each. Following this transaction, the total number of shares held in Treasury increased to 257,482,678. The total number of shares in issue (excluding Treasury shares) stands at 5,751,682,511, which represents the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Share Repurchase Volume: 630,000 shares purchased on February 28, 2007.
- Repurchase Price: 1,431.85 pence per share.
- Treasury Holdings: Total Treasury shares now stand at 257,482,678.
- Shares in Issue: 5,751,682,511 shares (excluding Treasury shares).
- Authority Source: Repurchase authorized by shareholders at the AGM on May 17, 2006.